Company intelligence / Profile preview
Nocion Therapeutics
Watertown / Waltham*, Massachusetts, United Statesnociontx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The lead program Taplucainium Dry Powder for Inhalation has advanced into a Phase 2b study in patients with chronic cough. The company’s approach selectively silences activated sensory neurons implicated in conditions like chronic cough and pain while minimizing off-target effects such as numbness or paralysis. Early results suggest potential benefits over standard sodium channel blockers and P2X3 antagonists.
- Therapeutic areas
- NeurologyPulmonologyDermatologyImmunology
- Modalities
- Small molecules (specifically, permanently charged sodium channel blockers called "nocions")
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Harvard University/Boston Children’s Hospital – exclusive license to foundational intellectual property from these institutionsNo major pharma partnerships publicly disclosed.
Beyond the preview
Go deeper on Nocion Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nocion Therapeutics.